Company Overview and News
The string of successive positive weeks for midstream ended this week. Midstream stocks were down roughly 1% across MLP and midstream indexes. Canadian Midstream stocks outperformed for the first time in a while. Utilities had a very strong week and the S&P was slightly positive. Oil prices continue to languish, now down 7 straight weeks, while natural gas prices continue to hold firm.
TGE CQP AMID PAGP ENB CEQP HCLP KMI HESM DKL TRP EBBNF OKE PAA ED KMR CVB NEE ENBBF TRP KEYUF LNG GLPRU ENLC ENB GBNXF ETP GLP SEMG TRGP KMRFZ
Devon Energy Corporation (DVN - Free Report) announced that it has entered into a definitive agreement to monetize its 9,600 net acres of non-core Delaware Basin acreage in Ward and Reeves County. The company sells the non-core asset to Carrizo Oil and Gas, Inc. (CRZO - Free Report) for $215 million. The deal was announced on Aug 14, 2018. The company monetized nearly $4.4 billion worth of assets year to date.
HD ENLK DVN OXY ENLC
The following slide deck was published by EnLink Midstream, LLC in conjunction with their 2018 Q2 earnings call.
Document Table of Contents UNITED STATES
The July MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
TGE SNSR MLPA AND LIT BFIT GXG SIL KRMA GXF DVN CHII TEP EV ACTX TEGP CHIE GOEX FINX CHIX SRET BOTZ CATH GURX ENLK BWP GURI ALUM MILN ENLC CJHIQ URA BHI LNGR COPX QQQC GURU
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET